BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 28250274)

  • 1. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
    Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
    Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
    Asai M; Kawakubo T; Mori R; Iwata N
    Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease.
    Ryoo SR; Cho HJ; Lee HW; Jeong HK; Radnaabazar C; Kim YS; Kim MJ; Son MY; Seo H; Chung SH; Song WJ
    J Neurochem; 2008 Mar; 104(5):1333-44. PubMed ID: 18005339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
    Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
    J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.
    Kimura R; Kamino K; Yamamoto M; Nuripa A; Kida T; Kazui H; Hashimoto R; Tanaka T; Kudo T; Yamagata H; Tabara Y; Miki T; Akatsu H; Kosaka K; Funakoshi E; Nishitomi K; Sakaguchi G; Kato A; Hattori H; Uema T; Takeda M
    Hum Mol Genet; 2007 Jan; 16(1):15-23. PubMed ID: 17135279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer's disease.
    Ryu YS; Park SY; Jung MS; Yoon SH; Kwen MY; Lee SY; Choi SH; Radnaabazar C; Kim MK; Kim H; Kim K; Song WJ; Chung SH
    J Neurochem; 2010 Nov; 115(3):574-84. PubMed ID: 20456003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-specificity tyrosine phosphorylation-regulated kinase 1A promotes the inclusion of amyloid precursor protein exon 7.
    Chu D; Lei L; Gu S; Liu F; Wu F
    Biochem Pharmacol; 2024 Jun; 224():116233. PubMed ID: 38663682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.
    Wegiel J; Dowjat K; Kaczmarski W; Kuchna I; Nowicki K; Frackowiak J; Mazur Kolecka B; Wegiel J; Silverman WP; Reisberg B; Deleon M; Wisniewski T; Gong CX; Liu F; Adayev T; Chen-Hwang MC; Hwang YW
    Acta Neuropathol; 2008 Oct; 116(4):391-407. PubMed ID: 18696092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity.
    Zhu B; Parsons T; Foley C; Shaw Y; Dunckley T; Hulme C; Hodge JJL
    Sci Rep; 2022 Sep; 12(1):15847. PubMed ID: 36151233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice.
    Mazur-Kolecka B; Golabek A; Kida E; Rabe A; Hwang YW; Adayev T; Wegiel J; Flory M; Kaczmarski W; Marchi E; Frackowiak J
    J Neurosci Res; 2012 May; 90(5):999-1010. PubMed ID: 22252917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.
    Pathak A; Rohilla A; Gupta T; Akhtar MJ; Haider MR; Sharma K; Haider K; Yar MS
    Eur J Med Chem; 2018 Oct; 158():559-592. PubMed ID: 30243157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
    Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
    J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
    Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
    Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perturbed Calcineurin-NFAT Signaling Is Associated with the Development of Alzheimer's Disease.
    Asai M; Kinjo A; Kimura S; Mori R; Kawakubo T; Shirotani K; Yagishita S; Maruyama K; Iwata N
    Biol Pharm Bull; 2016; 39(10):1646-1652. PubMed ID: 27725441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination Alzheimer's therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice.
    Devi L; Ohno M
    Mol Brain; 2015 Mar; 8():19. PubMed ID: 25884928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions.
    Higuchi M; Iwata N; Saido TC
    Biochim Biophys Acta; 2005 Aug; 1751(1):60-7. PubMed ID: 16054018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
    Chen XQ; Salehi A; Pearn ML; Overk C; Nguyen PD; Kleschevnikov AM; Maccecchini M; Mobley WC
    Alzheimers Dement; 2021 Feb; 17(2):271-292. PubMed ID: 32975365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dyrk1 inhibition improves Alzheimer's disease-like pathology.
    Branca C; Shaw DM; Belfiore R; Gokhale V; Shaw AY; Foley C; Smith B; Hulme C; Dunckley T; Meechoovet B; Caccamo A; Oddo S
    Aging Cell; 2017 Oct; 16(5):1146-1154. PubMed ID: 28779511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome.
    Sun X; He G; Song W
    FASEB J; 2006 Jul; 20(9):1369-76. PubMed ID: 16816112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.